sorry, we can't preview this file

...but you can still download s41467-020-20223-y (1).pdf
s41467-020-20223-y (1).pdf (3.13 MB)

Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy.

Download (3.13 MB)
journal contribution
posted on 19.01.2021, 14:43 by Mylène Tajan, Marc Hennequart, Eric C Cheung, Fabio Zani, Andreas K Hock, Nathalie Legrave, Oliver DK Maddocks, Rachel A Ridgway, Dimitris Athineos, Alejandro Suárez-Bonnet, Robert L Ludwig, Laura Novellasdemunt, Nikolaos Angelis, Vivian SW Li, Georgios Vlachogiannis, Nicola Valeri, Nello Mainolfi, Vipin Suri, Adam Friedman, Mark Manfredi, Karen Blyth, Owen J Sansom, Karen H Vousden
Many tumour cells show dependence on exogenous serine and dietary serine and glycine starvation can inhibit the growth of these cancers and extend survival in mice. However, numerous mechanisms promote resistance to this therapeutic approach, including enhanced expression of the de novo serine synthesis pathway (SSP) enzymes or activation of oncogenes that drive enhanced serine synthesis. Here we show that inhibition of PHGDH, the first step in the SSP, cooperates with serine and glycine depletion to inhibit one-carbon metabolism and cancer growth. In vitro, inhibition of PHGDH combined with serine starvation leads to a defect in global protein synthesis, which blocks the activation of an ATF-4 response and more broadly impacts the protective stress response to amino acid depletion. In vivo, the combination of diet and inhibitor shows therapeutic efficacy against tumours that are resistant to diet or drug alone, with evidence of reduced one-carbon availability. However, the defect in ATF4-response seen in vitro following complete depletion of available serine is not seen in mice, where dietary serine and glycine depletion and treatment with the PHGDH inhibitor lower but do not eliminate serine. Our results indicate that inhibition of PHGDH will augment the therapeutic efficacy of a serine depleted diet.

Funding

Crick (Grant ID: 10557, Grant title: Vousden FC001557) Crick (Grant ID: 10105, Grant title: Li FC001105) Cancer Research UK (Grant ID: C596/A26855, Grant title: CRUK C596/A26855)

History

Licence

Exports